BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29203143)

  • 1. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
    Wang L; Xu S; Chen X; Liu X; Duan Y; Kong D; Zhao D; Zheng P; Tang Q; Zhu W
    Bioorg Med Chem; 2018 Jan; 26(1):245-256. PubMed ID: 29203143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents.
    Wang L; Xu S; Liu X; Chen X; Xiong H; Hou S; Zou W; Tang Q; Zheng P; Zhu W
    Bioorg Chem; 2018 Apr; 77():370-380. PubMed ID: 29421713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
    Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, docking, molecular dynamics and bioevaluation studies on novel N-methylpicolinamide and thienopyrimidine derivatives with inhibiting NF-κB and TAK1 activities: Cheminformatics tools RDKit applied in drug design.
    Wang L; Zhang Q; Wang Z; Zhu W; Tan N
    Eur J Med Chem; 2021 Nov; 223():113576. PubMed ID: 34153577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.
    Liu J; Gong Y; Shi J; Hao X; Wang Y; Zhou Y; Hou Y; Liu Y; Ding S; Chen Y
    Eur J Med Chem; 2020 May; 194():112244. PubMed ID: 32224380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
    Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
    Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.
    Liu J; Yang D; Yang X; Nie M; Wu G; Wang Z; Li W; Liu Y; Gong P
    Bioorg Med Chem; 2017 Aug; 25(16):4475-4486. PubMed ID: 28716639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
    Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 2-oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide moiety.
    Tang Q; Zhai X; Tu Y; Wang P; Wang L; Wu C; Wang W; Xie H; Gong P; Zheng P
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1794-8. PubMed ID: 26944614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
    Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors.
    Liu X; Kou J; Xiao Z; Tian F; Hu J; Zheng P; Zhu W
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29949931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
    Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides.
    Wang M; Wu C; Xu S; Zhu Y; Li W; Zheng P; Zhu W
    Med Chem; 2017; 13(2):176-185. PubMed ID: 27855595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.